Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?"

Carmen Balana^{1

2}, Cristina Carrato³, Maria Angeles Vaz⁴

Affiliations

¹ Medical Oncology Service, Catalonian Institute of Oncology, Badalona, Spain.
² Applied Research Group in Oncology, Institute for Health Science Research Germans Trias I Pujol, Badalona, Spain.
³ Pathology Service, the Germans Trias University Hospital, Badalona, Spain.
⁴ Medical Oncology Service, Hospital Ramón y Cajal, Madrid, Spain.

Comment

Carmen Balana et al. Neuro Oncol. 2020.

. 2020 Dec 18;22(12):1889-1890.

doi: 10.1093/neuonc/noaa209.

Carmen Balana^{1

2}, Cristina Carrato³, Maria Angeles Vaz⁴

¹ Medical Oncology Service, Catalonian Institute of Oncology, Badalona, Spain.
² Applied Research Group in Oncology, Institute for Health Science Research Germans Trias I Pujol, Badalona, Spain.
³ Pathology Service, the Germans Trias University Hospital, Badalona, Spain.
⁴ Medical Oncology Service, Hospital Ramón y Cajal, Madrid, Spain.

No abstract available

Comment on

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
Balana C, Vaz MA, Manuel Sepúlveda J, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C. Balana C, et al. Neuro Oncol. 2020 Dec 18;22(12):1851-1861. doi: 10.1093/neuonc/noaa107. Neuro Oncol. 2020. PMID: 32328662 Free PMC article. Clinical Trial.
Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?
Gupta T, Chatterjee A, Patil V. Gupta T, et al. Neuro Oncol. 2020 Dec 18;22(12):1887-1888. doi: 10.1093/neuonc/noaa194. Neuro Oncol. 2020. PMID: 32777076 Free PMC article. No abstract available.

1. Stupp R, Mason WP, van den Bent MJ, et al. ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. - PubMed
1. Perry JR, Laperriere N, O’Callaghan CJ, et al. ; Trial Investigators Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–1037. - PubMed
1. Chinot OL, Wick W, Mason W, et al. . Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722. - PubMed
1. Gilbert MR, Wang M, Aldape KD, et al. . Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–4091. - PMC - PubMed
1. Gilbert MR, Dignam JJ, Armstrong TS, et al. . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. - PMC - PubMed